Skip to content

AUSTRALIA

What is Cask ?

CASK is an abbreviation of the gene’s full name, calcium/calmodulin-dependent serine protein kinase.

The CASK gene provides instructions for producing the CASK protein, which is essential for normal brain development and function.

A brain without proper cask function cannot keep up with the normal rate of brain growth after birth.

A CASK gene mutation refers to a change or alteration in the DNA sequence of the CASK gene. Mutations in this gene can disrupt the normal functioning of the protein, leading to various neurodevelopmental disorders.

The main 2 disorders are:

  • microcephaly with pontine and cerebellar hypoplasia (MICPCH); and
  • X-linked intellectual disability (XL-ID) with or without nystagmus.

CASK gene disorders can affect both males and females, but there are some differences in how these disorders manifest in each gender. The primary reason for these differences is related to the X chromosome inheritance pattern, as the CASK gene is located on the X chromosome.

Males have one X chromosome and one Y chromosome (XY), while females have two X chromosomes (XX). Males are usually affected more profoundly because they only have a single copy of the X chromosome that carries the mutation.

On the other hand, females have a second unaffected copy of the CASK gene on their other X chromosome that can partially compensate for the loss or altered function of the affected gene copy. However, one X chromosome in each cell is ‘inactivated’ and the effect of X-inactivation on CASK-related disorders in girls is not yet fully understood.

what is Cask
Cask Gene

CASK Population & Mortalities

As of August 2023, there are 277 CASK Individuals reported by families as having CASK.

CASK families have reported 11 deaths between 2016 and 2023.

“In some ways, that CASK-linked pathology is degenerative in nature provides a positive outlook. Because microcephaly in CASK-linked pathology progresses postnatally, there may be a temporal window when therapeutic intervention might prevent or slow further brain cell loss. Regression, even in adolescence, has also been observed in some cases of MICPCH [119], again offering the tantalizing possibility that a therapeutic approach might prevent such decline under conditions when degeneration is known to progressThe potential benefits of intervention might extend even further given that non-cell-autonomous toxicity could also affect functioning of the remaining neurons; reduction of such toxicity, especially when coupled with high-intensity rehabilitative measures [120], might offer real hope for a positive impact on functional outcomes.”   

https://www.mdpi.com/2073-4409/11/7/1131/htm